Itonis, Inc. Signed Exploratory Analysis Trial for Cloud9 Project With Valley Organics Inc.

LAGUNA HILLS, CA--(Marketwired - Apr 16, 2014) - Itonis, Inc. (PINKSHEETS: ITNS) today announced that it has signed an agreement with Valley Organics Inc. to start a 30-day "Exploratory Analysis Trial" for the Company's cannabinoid-based product that is presently named as its Cloud9 project.

Valley Organics Inc. is not a wholly owned asset of nor affiliated with Latteno Food Corp.

The initial 200mg Cloud9 product is not for sale or distribution, it is only for the Exploratory Analysis Trial purposes only.

The Company expects that upon Valley Organics' completion of the Exploratory Analysis Trial, the Company will be in a position to manufacture the Cloud9 product for distribution.

The Company has been developing the Cloud9 product as a unique sublingual that dissolves under the tongue as a convenient delivery method. The manufacturing of the Cloud9 product will use a Supercritical CO₂ Extraction process to extract cannabinoids ("CBDs") from hemp oil within lawful parameters. The Company plans on making Cloud9 available in a unit range of 100 - 200 mg.

About Valley Organics Inc.
Southern California-owned and licensed medical marijuana co-op and transporting. The specific purpose of this corporation is to collectively facilitate medical marijuana cultivation and transactions by and between qualified patient members of this corporation and/or primary caregiver members who have the oral or written approval or recommendation of a licensed physician, as permitted and authorized by the Compassionate Use Act of 1996 (Health and Safety Code section 11362.5) and the Medical Marijuana Program Act (Health and Safety Code sections 11362.7 - 11362.83). 

About Itonis, Inc.

Itonis, Inc. was incorporated in the state of Nevada on July 5, 2005 under the name of Kenshou, Inc., which later changed to Itonis, Inc. on December 2, 2005. Please visit www.itonisholdings.com.

Safe Harbor:

Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.